Astrazeneca Strategic Business Analysis
Table of content
Chapter Title Page
1.1 Introduction and background 3
1.2 Methodology 4
2.1 Key opportunities 5
2.2 Key challenges 6
3 Internal and Industry Analysis 7
3.1 Porter’s six forces analysis 7
3.2 Financial position 8
3.3 Product position 9
3.4 Pipeline developments 11
3.5 R&D analysis 13
3.6 AstraZeneca innovative partnership 14
4 Strategy Evaluation 15
5 Conclusion 16
6 References 17
7 Appendix 18
EXECUTIVE SUMMARY:
Chapter Title Page
1.1 Introduction and background 3
1.2 Methodology 4
2.1 Key opportunities 5
2.2 Key challenges 6
3 Internal and Industry Analysis 7
3.1 Porter’s six forces analysis 7
3.2 Financial position 8
3.3 Product position 9
3.4 Pipeline developments 11
3.5 R&D analysis 13
3.6 AstraZeneca innovative partnership 14
4 Strategy Evaluation 15
5 Conclusion 16
6 References 17
7 Appendix 18
EXECUTIVE SUMMARY:
References: AstraZeneca’s main six therapy areas represent a significant proportion of the worldwide burden of disease as projections indicate the burden of disease (chronic disease) will continue to increase next 20 years. On September 21, 2009, the U.S